# Tirzepatide: one molecule, three approvals, three different dates > Tirzepatide: Research Overview — Buy Canadian Peptides — Tirzepatide within Research Peptide Fundamentals research peptides: a dual GIP and GLP-1 receptor agonist, approved in stages across three indications, with head-to-head trial results and a safety picture read entirely from randomised evidence. **04 / TIRZEPATIDE — APPROVED IN STAGES** A dual-receptor agonist whose regulatory history is the cleanest illustration on this desk that approval is granted indication by indication — and that the calendar runs separately in every country that keeps one. ## The short version Tirzepatide is a synthetic peptide that switches on two gut-hormone receptors at once — GLP-1, the same target as semaglutide, and GIP, a second incretin receptor that semaglutide leaves alone. That is the whole design idea, and in trials it has translated into larger effects. In a 72-week head-to-head trial in 751 adults with obesity, mean weight change was -20.2% with tirzepatide against -13.7% with semaglutide [11]. In a separate 72-week placebo-controlled trial in 2,539 adults with obesity, weight fell 15.0%, 19.5% and 20.9% at three ascending amounts, against 3.1% with placebo [20]. It was approved for type 2 diabetes in May 2022 [18], and only later for chronic weight management, and later still for moderate-to-severe obstructive sleep apnoea in adults with obesity. Three separate decisions about one unchanged molecule — which is exactly the point this desk keeps returning to. ## What it is Tirzepatide is a synthetic incretin-mimetic peptide and a dual agonist: it activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Most of the class that preceded it engaged one of those two. The distinction matters when reading claims about it. A single-agonist GLP-1 medicine and a dual GIP/GLP-1 agonist are different pharmacological objects even when the endpoints they are tested against look identical, and the head-to-head trials on this page exist precisely because the difference could not be assumed from mechanism alone. In regulatory terms it is a prescription-only medicine wherever it is approved. The reference source for this page notes that its weight-loss use was, at the time of writing, an off-label application relative to the original diabetes approval, and that the agent is not approved for type 1 diabetes [18] — a snapshot that later approvals have moved, and a good reminder that any statement about approval status carries an implicit date. ## How it works Tirzepatide engages two incretin receptors simultaneously. GLP-1 receptor activation potentiates glucose-dependent insulin release, restrains glucagon, and slows gastric emptying, with central effects on appetite. GIP receptor activation adds a second incretin signal that acts on the pancreas and on adipose tissue, and the working hypothesis behind the molecule is that the two arms together do more than either alone. Because insulin secretion is stimulated in a glucose-dependent way, hypoglycaemia risk from the drug by itself is low, and trials repeatedly reported high proportions of participants reaching glycaemic targets without it. That changes when it is combined with a sulfonylurea or with insulin, where the label advises that a lower amount of the concomitant agent may be needed. The delay in gastric emptying is transient and attenuates with continued exposure. It is also the mechanism behind two of the practical cautions further down this page: retained stomach contents have been observed at upper-gastrointestinal endoscopy, and the absorption of co-administered oral medicines can be altered. ## What the research shows The tirzepatide evidence base is young but unusually well designed, and it is worth reading with the study designs attached rather than the headline numbers alone. **Against placebo.** SURMOUNT-1 was a 72-week phase 3 double-blind randomised controlled trial in 2,539 adults with obesity — a body-mass index of 30 or more, or 27 or more with a weight-related complication — and without diabetes. Mean weight change at week 72 was -15.0% at the lowest of three amounts, -19.5% at the middle and -20.9% at the highest, against -3.1% with placebo. The commonest adverse events were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation [20]. **Against semaglutide, in obesity.** SURMOUNT-5 was a phase 3b *open-label* head-to-head trial in 751 adults with obesity and without type 2 diabetes, randomised to the maximum tolerated amount of either agent once weekly for 72 weeks. Least-squares mean weight change at week 72 was -20.2% with tirzepatide against -13.7% with semaglutide (P<0.001), with a greater reduction in waist circumference and higher proportions reaching the 10%, 15%, 20% and 25% weight-loss thresholds [11]. Open-label design is a real limitation on a subjective-behaviour endpoint, and it is the first thing a careful reader notes about this trial. **Against semaglutide, in diabetes.** SURPASS-2 was an open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes. Glycated haemoglobin fell by an estimated 2.01, 2.24 and 2.30 percentage points across the three tirzepatide amounts, against 1.86 percentage points with semaglutide 1 mg — non-inferior and superior at all three. Weight reductions were greater with tirzepatide, with treatment differences of -1.9, -3.6 and -5.5 kg. Adverse events were again mostly mild-to-moderate gastrointestinal ones [21]. The comparator amount matters here: semaglutide 1 mg is a diabetes amount, not the higher weight-management one. **Two specific safety signals, tested directly.** A systematic review and meta-analysis of nine randomised controlled trials covering 9,871 participants examined pancreatitis and gallbladder or biliary disease against controls — basal insulin, selective GLP-1 receptor agonists, or placebo. Tirzepatide was not associated with a statistically significant increase in pancreatitis (RR 1.46, 95% CI 0.59-3.61), but was associated with a significantly increased risk of the composite of gallbladder or biliary disease (RR 1.97, 95% CI 1.14-3.42), with no individual component reaching significance on its own [19]. Every amount named here is what the cited trials administered. Nothing on this page recommends one. ## Reported effects, cautions and safety The following community material is **anecdotal, not clinical evidence** — drawn from patient interviews, community discussion and post-market reporting, unverified, and carrying no amounts here. The benefit described most consistently is the same quieting of intrusive food-related thought that dominates the semaglutide reports: the mental loop of meal planning and snack anticipation fading, with some people saying they forget to eat. Increased energy and less sluggishness are commonly described as weight declines, as are improved mood and self-confidence in structured exit interviews. Better sleep is a recurring theme, including reduced snoring and, among people with a prior sleep-apnoea diagnosis, easier nights. Reduced joint pain and easier movement are frequently reported by those who have lost substantial weight. Self-reported improvements in glucose readings and lipid results appear often. On the adverse side, nausea after each increase is the most commonly reported effect, typically peaking in the first week or two of a new amount and fading. Alternating constipation and loose stools is widely described and tied to slowed gastric emptying. Sulfurous burping is reported by a subset. Injection-site reactions — pain, redness, bruising, small lumps — are among the most frequently reported categories in post-market data. Metallic or altered taste and sudden aversions to previously enjoyed foods come up regularly. Weight-loss plateaus lasting weeks are widely discussed and described by clinicians as a normal part of the arc rather than a failure. Concern about losing muscle alongside fat is common among people who train. Hair thinning some months in is reported by a subset and attributed to the speed of weight loss rather than to the drug. The documented cautions rest on firmer evidence: - **Gastrointestinal intolerance during escalation.** Nausea, vomiting, diarrhoea, constipation and decreased appetite are by far the commonest adverse effects, emerging chiefly during stepwise increases and generally easing with continued exposure; the trial record describes them as mostly mild to moderate and concentrated in the escalation period [20]. - **Thyroid C-cell tumours and MEN-2 (boxed warning).** The prescribing information carries a boxed warning derived from rodent studies in which the incretin class caused dose- and duration-dependent thyroid C-cell tumours. Whether that translates to humans is not established, and the label excludes people with a personal or family history of medullary thyroid carcinoma or MEN-2 [18]. - **Pancreatitis.** A recognised class concern, monitored on the label and captured in post-marketing reporting, but the dedicated meta-analysis of nine randomised trials found no statistically significant increase against controls (RR 1.46, 95% CI 0.59-3.61) [19]. - **Gallbladder and biliary disease.** The same meta-analysis found a significantly increased risk of the composite outcome (RR 1.97, 95% CI 1.14-3.42) [19]. - **Hypoglycaemia in combination.** Low on its own because insulin secretion is glucose-dependent, but the risk rises when added to a sulfonylurea or insulin, and the label advises that the concomitant agent may need reducing. - **Delayed gastric emptying and sedation.** Retained gastric contents have been observed at upper-gastrointestinal endoscopy, which is a theoretical aspiration concern under sedation or general anaesthesia. - **Reduced oral-contraceptive reliability.** Because gastric emptying is slowed, the prescribing information advises that oral hormonal contraceptive effectiveness may be reduced, particularly around the initial amount and each increase, with a non-oral or barrier method as the label-suggested mitigation. - **Lean-mass and skeletal-muscle loss.** As with potent incretin therapies generally, a meaningful fraction of the weight lost is lean rather than fat mass, and the rapidity of that loss is an active research question. - **Dehydration and acute kidney injury.** Severe or prolonged vomiting, diarrhoea and reduced fluid intake can cause volume depletion, the proposed route by which incretin therapies could precipitate acute kidney injury, particularly alongside diuretics, ACE inhibitors or ARBs. - **Weight regain after stopping.** Withdrawal data show substantial regain proportional to the amount initially lost, and a dedicated withdrawal trial showed participants switched to placebo regaining weight while those continuing kept losing. - **A tolerability-efficacy trade-off.** Overall and serious adverse-event rates are broadly comparable to other incretins, but discontinuation due to adverse events is higher, driven largely by gastrointestinal effects. - **Hair loss.** Reversible diffuse shedding is reported, attributed largely to the physiological stress of rapid weight reduction rather than direct toxicity, and typically self-limiting once weight stabilises. ## Where it sits on the jurisdictional map Tirzepatide is the best worked example on this desk of a fact that gets flattened in almost every online discussion: approval is granted *for an indication*, not for a molecule. The United States record shows it plainly. First approval, May 2022, for type 2 diabetes [18]. A second approval, in November 2023, for chronic weight management in adults with obesity or with overweight plus a weight-related condition. A third, later, for moderate-to-severe obstructive sleep apnoea in adults with obesity. Between the first and the second, a clinician could prescribe it and a person could take it, while the weight-loss use sat outside the approved label — which is why the reference source for this page describes weight-loss efficacy as an off-label use [18], a description that was accurate when written and is not a permanent property of the drug. Now multiply that by every country that maintains its own register. Each one grants each indication on its own schedule, on its own reading of the same trials, after its own filing. Two countries can therefore hold entirely different views of what tirzepatide is *for* on the same day, with no disagreement whatsoever about SURMOUNT-1 or SURPASS-2. A claim like "it is approved for weight loss" is incomplete until it names both a country and a date. In sport, tirzepatide is not specifically prohibited as a performance-enhancing agent under the World Anti-Doping Agency's list, though it is a prescription medicine and any use is expected to follow medical and regulatory guidance. The practical reading rule follows directly. An approval status found online is a snapshot of one jurisdiction at one moment. Reading it as a property of the molecule is the single commonest error in this whole subject, and tirzepatide — same molecule, three approvals, three dates, and a different sequence in every country — is the cleanest place to see why. --- Buy Canadian Peptides is a citation-indexed reading desk on how different countries categorise the same molecules — it sells nothing, names no seller in any jurisdiction, and treats a gap between two regulators as a fact to explain rather than an offer to make.